Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | CA6 | P23280 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | CTRC | Q99895 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157465 | 1.00 | NOS1 (0.44) | NOS1NOS2CA1CA2CA4 | |
| SCHEMBL10502755 | 1.00 | NOS1 (0.44) | NOS1NOS2CA1CA2CA4 | |
| SCHEMBL21297485 | 0.98 | NOS1 (0.46) | NOS1NOS2CA1CA2CA4 | |
| SCHEMBL528992 | 0.98 | NOS1 (0.46) | NOS1NOS2CA1CA2CA4 | |
| Ethylene SCHEMBL6509460 | 0.96 | NOS1 (0.44) | NOS1NOS2CA1CA2CA4 | |
| SCHEMBL2051321 | 0.92 | — | — | |
| SCHEMBL3942028 | 0.92 | — | — | |
| SCHEMBL15423555 | 0.92 | — | — | |
| SCHEMBL29886436 | 0.92 | — | — | |
| SCHEMBL3259636 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330138-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-10-31 | — | — | US | disclosed |
| US-10392338-B2 | Spirofuranone compounds, derivatives thereof and processes for their preparation | Yissum Research Development Company, of The Hebrew University of Jerusalem Ltd. (IL) | 2019-08-27 | — | — | US | disclosed |
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-01-18 | — | — | US | disclosed |
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-01-18 | — | — | US | disclosed |
| EP-3250559-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2017-12-06 | — | — | EP | disclosed |
| CN-107207455-A | Spirofuranone compounds, derivatives thereof and processes for their preparation | 耶路撒冷希伯来大学伊森姆研究发展公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2016120879-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016120879-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-08-04 | — | — | WO | disclosed |
| US-8415347-B2 | Substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | disclosed |
| US-8404729-B2 | Heterocyclic tetracyclic tetrahydrofuran derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-6046211-A | TREATMENT OF ARTHRITIS OR INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA (ALLODYNIA), CEREBRAL ISCHEMIA AND OTHER CNS DISORDERS | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | disclosed |
| US-6043261-A | TREATMENT OF INFLAMMATORY CONDITIONS AFFECTING THE JOINTS, FOR EXAMPLE ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA, CEREBRAL ISCHEMIA, THROMBOTIC STROKE, GLOBAL ISCHEMIA, NERVOUS SYSTEM DISORDERS | G. D. SEARLE & CO. (US) | 2000-03-28 | — | — | US | disclosed |
| US-6011028-A | Cyclic amidino agents useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5883251-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0897912-A1 | Amidino derivatives useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 1999-02-24 | — | — | EP | disclosed |
| US-5854234-A | Amidino dervatives useful as nitric oxide synthase inhibitors | G. D. SEARLE & CO. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033175-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0724570-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011231-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392338-B2 | Spirofuranone compounds, derivatives thereof and processes for their preparation | PKD1, PKD2, DHPS | NOS1 3925/4885NOS2 3875/4885CA1 3892/4885 |
| US-20180016221-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | PKD1, PKD2, DHPS | NOS1 3925/4885NOS2 3875/4885CA1 3892/4885 |
| US-20190330138-A1 | SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION | PKD1, PKD2, DHPS | NOS1 3925/4885NOS2 3875/4885CA1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.